Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares Core S&P 500 ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares Core S&P 500 ETF trades at $770.84 (market cap $896.46B). The key difference: iShares Core S&P 500 ETF is far larger — about 87.5× Globus Medical Inc. Class A Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares Core S&P 500 ETF for 46 Days on average.
| GMED | IVV | |
|---|---|---|
Market Cap | $10.25B | $896.46B |
Volume | 1,059,528 | 4,999,099 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $782.58 |
52-Week Low | $58.33 | $634.93 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
IVV, tracking the S&P 500, trades at $781.42 with minimal daily change. Technical analysis shows a bullish trend with strong moving average support, though RSI indicates potential overbought conditions near-term. The ETF benefits from broad market exposure amid expectations of continued corporate profit growth, with S&P 500 earnings projected to rise 35% in 2026 according to 24/7 Wall Street on October 3, 2026.
Outlook remains positive given historical seasonal trends and strong institutional support, but risks include concentration in top holdings and potential profit growth deceleration. The ETF's low-cost structure and diversification provide stability, though market volatility and economic shifts could challenge near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
